Season 3, Episode 4 (Oral Minoxidil for AGA, JAKI for AGA, PRP for AGA,COVID Vaccines and AA Risk, AA Rising Prevalence)

1:46:52
 
Поширити
 

Manage episode 346460468 series 3312560
Зроблено Dr Jeff Donovan і знайдено завдяки Player FM та нашій спільноті. Авторські права належать видавцю, а не Player FM, і аудіоматеріали транслюються безпосередньо з сервера видавця. Натисніть на кнопку Підписатися, щоб слідкувати за оновленнями в Player FM або скопіюйте і вставте посилання на канал до іншої програми для подкастів.

Studies in Androgenetic Alopecia and Alopecia Areata

STUDIES REFERENCED

MINOXIDIL CONCENTRATIONS

Singh et al (starts at 10:10). Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit? Clin Exp Dermatol. 2022 Nov;47(11):1951-1955

Olsen EA, Dunlap FE, Funicella T et al (starts at 13:22). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47: 377–85

McCoy J, Goren A, Kovacevic M, Shapiro J (starts at 16:02). Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents 2016;30: 1153–5

Goldust M (starts at 17:25). Minoxidil 15% solution versus minoxidil 5%solution in the treatment of androgenetic alopecia. Br JDermatol 2020;183(Suppl): 91 (abstract BH107)

Ghonemy S, Alarawi A, Bessar H (starts at 18:11). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgeneticalopecia: a trichoscopic evaluation. J Dermatolog Treat 2021;32: 236–41

JAK INHBITORS FOR ANDROGENETIC ALOPECIA

Casale F et al (starts at 22:19). Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia? Int J Dermatol. 2022 Nov;61(11):e457-e458.

BOTOX FOR ANDROGENETIC ALOPECIA

English RS Jr and Ruiz S (starts at 29:30). Use of Botulinum Toxin for Androgenic Alopecia: A Systematic Review. Skin Appendage Disord. 2022 Mar;8(2):93-100

Shon U, Kim MH, Lee DY, Kim SH, Park BC (starts at 33:48). The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism. J Am Acad Dermatol. 2020 Dec;83(6):1838–9.

PLATELET RICH PLASMA TREATMENTS FOR ANDROGENETIC ALOPECIA

Gupta AK and Bamimore M (starts at 39:09). Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.

de Oliveira AFQ et al (starts at 42:25). Use of autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and meta-analysis. J Dermatolog Treat. 2022 Oct 31:1-11.

LOW DOSE ORAL MINOXIDIL SIDE EFFECTS

Dlova et al (starts 45:41). Pericardial, pleural effusion and anasarca: A rare complication of low-dose oral minoxidil for hair loss. JAAD Case Rep. 2022 Aug 11;28:94-96.

Randolph M, Tosti A (starts at 53:22). Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021;84(3): 737-746.

LOW DOSE ORAL MINOXIDIL EFFICACY AND SAFETY

Gupta AK et al (starts at 57:33). There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36

JAK INHIBITORS AND VENOUS THROMBOEMBOLISM

Chen T-L et al (starts at 1:02:14). Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis. JAMA Dermatol. 2022 Aug 24;e223516.

King B et al (1:05:33). Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 Mar 26.

Misra D et al (starts at 1:11:19). Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box. Clin Rheumatol. 2022 Oct 20.

RISING PREVALENCE OF ALOPECIA AREATA IN JAPAN

Campos-Alberto E et al (starts at 1:13:00). Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: A descriptive study using Japan medical data center claims database. J Dermatol. 2022 Nov 2.

COVID VACCINATION AND ALOPECIA AREATA RISK

Tassone F et al (starts at 1:15:21). Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study. Vaccines (Basel). 2022 Sep 5;10(9):1467.

Nguyen B and Tosti A (starts at 1:21:22). Alopecia areata after COVID-19. J Eur Acad Dermatol Venereol. 2022 Aug 11;10.1111/jdv.18491.

Babadjouni A et al (starts at 1:30:21). COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy. JAAD Case Rep . 2022 Nov;29:181-185.

Chen C-H et al (starts at 1:36:55). Intractable alopecia areata following the second dose of COVID-19 vaccination: Report of two cases. Dermatol Ther. 2022 Sep;35(9):e15689.

33 епізодів